A study evaluated the efficacy of gefitinib combined with cetuximab for patients with advanced/metastatic NSCLC previously treated with platinum-based chemotherapy without EGFR mutation or amplification, and the results showed that none achieved partial response (PR) (59). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.